AXIM · Axim Biotechnologies, Inc. · Executive Compensation
$0.00
+0.00 (+3.33%)
At close · Oct 23
Return incl. dividend (before tax)
Going-concern doubt
— flagged Aug 19, 2024
Substantial doubt about the company's ability to continue as a going concern.
“These conditions raise substantial doubt about the ability of the Company to continue as a going concern. The financial statements do not include any adjustments related to the recoverability of assets and classification of liabilities that might be necessary should the Company be unable to continue in operation.”View the 10-Q filed Aug 19, 2024
Market Cap
$905,876
Shares
301.96M
Volume · Oct 23
114K
Avg daily vol (3M)
387.06K
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
No Compensation Data
No Summary Compensation Table has been imported from this company's proxy statements yet.
Executive changes
| Person | Role | Change | Filed |
|---|---|---|---|
| Catalina Valencia | Series C Director | Appointed | 2024-10-15 |
| Catalina Valencia | President | Appointed | 2024-10-15 |
| Kurt Phinney | Chief Operating Officer | Appointed | 2023-05-25 |
Leadership
- Kurt Phinney COO
- Blake N. Schroeder Board Member
- Catalina Valencia Board Member
- Peter O'Rourke Board Member